Study of Anti-mullerian Hormone as a Diagnostic Criteria for Polycystic Ovarian Syndrome

A BSTRACT Background: PCOS is most common endocrine disorders among women of reproductive age group. This syndrome has varied manifestations affecting the females of all age groups. Rotterdam criteria are the most used for the diagnosis of PCOS. AMH is a newer marker which is secreted much more by the polycystic ovaries compared to normal ovaries and is not affected by day of menstrual cycle and even use of OCPs. Due to persistent controversies regarding diagnosis of PCOS due to its complex presentation and to evaluate ovarian morphology, AMH can be used as a new quantitative and biologic marker for PCOS. Methods: This was a case–control study performed on women attending Gynaecology OPD at a tertiary care hospital. The study consisted of 100 women with PCOS, diagnosed using Rotterdam criteria and 173 women as controls. Clinical profile, clinical examination, BMI, blood investigations like FSH, LH, TSH, prolactin and AMH levels were assessed. Sonography of the pelvis to see the ovarian morphology was done for all women. Results: AMH levels in PCOS cases were on average 8.16 ng/ml, which was significantly higher than controls’ levels of 3.05 ng/ml (p = 0.001). AMH produced sensitivity of 83% when employed as a supplement to the current Rotterdam criteria as the fourth criterion. However, when AMH was used in place of PCOM in the Rotterdam criterion, AMH produced a sensitivity of 89%. Conclusion: To conclude AMH levels were considerably greater in PCOS. AMH values offer good diagnostic potential when used in conjunction with the current Rotterdam criteria for the diagnosis of PCOS